Equities analysts expect that Syros Pharmaceuticals Inc (NASDAQ:SYRS) will post earnings of ($0.50) per share for the current quarter, Zacks Investment Research reports. Five analysts have made estimates for Syros Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.48) and the lowest estimate coming in at ($0.53). Syros Pharmaceuticals reported earnings per share of ($0.58) in the same quarter last year, which would suggest a positive year over year growth rate of 13.8%. The firm is scheduled to issue its next earnings report on Monday, March 11th.
According to Zacks, analysts expect that Syros Pharmaceuticals will report full-year earnings of ($1.87) per share for the current fiscal year, with EPS estimates ranging from ($1.90) to ($1.85). For the next year, analysts anticipate that the company will report earnings of ($1.93) per share, with EPS estimates ranging from ($2.11) to ($1.80). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side analysts that follow Syros Pharmaceuticals.
Syros Pharmaceuticals (NASDAQ:SYRS) last issued its earnings results on Thursday, November 1st. The company reported ($0.47) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.45) by ($0.02). The firm had revenue of $0.41 million for the quarter, compared to analyst estimates of $0.72 million.
A number of equities research analysts have recently commented on the stock. BidaskClub upgraded shares of Syros Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, August 31st. Zacks Investment Research upgraded shares of Syros Pharmaceuticals from a “hold” rating to a “buy” rating and set a $13.00 target price for the company in a research report on Friday, August 10th. Roth Capital upgraded shares of Syros Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $12.00 target price for the company in a research report on Monday, November 5th. Wedbush reiterated an “outperform” rating and issued a $13.00 target price on shares of Syros Pharmaceuticals in a research report on Monday. Finally, JMP Securities set a $33.00 target price on shares of Syros Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, November 1st. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $19.29.
Several institutional investors and hedge funds have recently made changes to their positions in the stock. Bank of New York Mellon Corp grew its holdings in shares of Syros Pharmaceuticals by 10.0% in the third quarter. Bank of New York Mellon Corp now owns 77,654 shares of the company’s stock valued at $925,000 after purchasing an additional 7,062 shares during the period. MetLife Investment Advisors LLC grew its holdings in shares of Syros Pharmaceuticals by 55.2% in the third quarter. MetLife Investment Advisors LLC now owns 20,338 shares of the company’s stock valued at $242,000 after purchasing an additional 7,230 shares during the period. JPMorgan Chase & Co. grew its holdings in shares of Syros Pharmaceuticals by 2.3% in the third quarter. JPMorgan Chase & Co. now owns 369,959 shares of the company’s stock valued at $4,406,000 after purchasing an additional 8,286 shares during the period. Rhumbline Advisers grew its holdings in shares of Syros Pharmaceuticals by 87.6% in the second quarter. Rhumbline Advisers now owns 22,472 shares of the company’s stock valued at $229,000 after purchasing an additional 10,494 shares during the period. Finally, Cubist Systematic Strategies LLC purchased a new stake in shares of Syros Pharmaceuticals in the second quarter valued at about $119,000. 61.26% of the stock is owned by hedge funds and other institutional investors.
Shares of NASDAQ SYRS traded up $0.17 during mid-day trading on Friday, reaching $7.67. The company’s stock had a trading volume of 84,000 shares, compared to its average volume of 174,471. The stock has a market capitalization of $235.58 million, a price-to-earnings ratio of -3.60 and a beta of 0.80. Syros Pharmaceuticals has a 1-year low of $6.25 and a 1-year high of $13.86.
About Syros Pharmaceuticals
Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; and SY-1365, a selective CDK7 inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian cancer, breast cancer, and AML.
Further Reading: Understanding Compound Annual Growth Rate (CAGR)
Get a free copy of the Zacks research report on Syros Pharmaceuticals (SYRS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.